Cytokinetics, Inc. (CYTK)

[H2R]

$10M milestone reached :)

CYTOKINETICS ANNOUNCES DOSING OF FIRST PATIENT IN JAPAN IN GALACTIC-HF, PHASE 3 CLINICAL TRIAL OF OMECAMTIV MECARBIL IN PATIENTS WITH HEART FAILURE

Company Earns $10 Million Milestone Payment from Amgen

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) --

Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that the first patient has been dosed in Japan in GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil which is being conducted by Amgen, in collaboration with Cytokinetics. Coincident with patient dosing, Amgen will make a $10 million milestone payment to Cytokinetics. Omecamtiv mecarbil, a novel investigational cardiac myosin activator that increases cardiac contractility, is being developed by Amgen in collaboration with Cytokinetics for the potential treatment of heart failure.